Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis (Journal for ImmunoTherapy of Cancer (2018) 6 (103) DOI: 10.1186/s40425-018-0412-0)

Abstract

Following publication of the original article [1], the authors reported an error in their listed affiliations. This error was introduced during typesetting and the publisher apologizes to readers and the authors for the inconvenience. In this Correction the authors are listed with their correct affiliations below. Daniel H Johnson1, Chrystia M Zobniw2, Van A Trinh2, Junsheng Ma3, Roland L Bassett Jr3, Noha Abdel-Wahab4,5, Jaime Anderson2, Jennifer E Davis6, Jocelyn Joseph2, Marc Uemura1, Ali Noman7, Hamzah Abu-Sbeih7, Cassian Yee1, Rodabe Amaria1, Sapna Patel1, Hussein Tawbi1, Isabella C Glitza1, Michael A Davies1, Michael K Wong1, Scott Woodman1, Wen-Jen Hwu1, Patrick Hwu1, Yinghong Wang7 and Adi Diab1. 1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2Division of Pharmacy, Clinical Section, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5Department of Rheumatology and Rehabilitation, Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt. 6Department of Epidemiology, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 7Department of Gastroenterology, Hepatology, and Nutrition, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.